Genetic Abnormalities in Neurodevelopmental Disorders with Multidimensional Impairment

IF 2.7 4区 医学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY
Cyril Hanin, Paloma Torres, Isabelle Millet, Joana Matos, Cora Cravero, Marianna Giannitelli, Anne-Sophie Pellen, Hugues Pellerin, Charline Grossard, Ingrid Zammouri, Astrid De Foucaud, Claudine Laurent-Levinson, David Cohen
{"title":"Genetic Abnormalities in Neurodevelopmental Disorders with Multidimensional Impairment","authors":"Cyril Hanin,&nbsp;Paloma Torres,&nbsp;Isabelle Millet,&nbsp;Joana Matos,&nbsp;Cora Cravero,&nbsp;Marianna Giannitelli,&nbsp;Anne-Sophie Pellen,&nbsp;Hugues Pellerin,&nbsp;Charline Grossard,&nbsp;Ingrid Zammouri,&nbsp;Astrid De Foucaud,&nbsp;Claudine Laurent-Levinson,&nbsp;David Cohen","doi":"10.1007/s12031-025-02424-6","DOIUrl":null,"url":null,"abstract":"<div><p>Objectives: Many children with neurodevelopmental disorders (NDD) show complex, multidimensional impairments meeting criteria for multiple NDD, yet remain “diagnostically homeless” as DSM-5 lacks a Multidimensional Impairment (MDI) category. We investigated the prevalence of genetic abnormalities in such complex NDD cases. Methods:Between 2017 and 2019, we diagnosed MDI in 666 patients. Among them, 122 (18%) underwent genetic assessment (DNA microarrays, karyotype, gene panels, FISH, FMR1 testing, exome/genome sequencing). We used univariate analyses and clustering to explore associations between clinical dimensions and genetic findings. Results: Genetic abnormalities were identified in 78 patients. Of these:</p><ol>\n <li>\n <span>(1)</span>\n \n <p>41 had known abnormalities usually linked to complex NDD (e.g., del22q11.2);</p>\n \n </li>\n <li>\n <span>(2)</span>\n \n <p>16 had mutations associated with severe ASD/ID (e.g., <i>GRIA3</i> on Xq25);</p>\n \n </li>\n <li>\n <span>(3)</span>\n \n <p>11 showed novel abnormalities not previously linked to NDD (e.g., duplication Xq21.1 including <i>POU3F4</i>);</p>\n \n </li>\n <li>\n <span>(4)</span>\n \n <p>10 had variants of uncertain significance.</p>\n \n </li>\n </ol><p> Depending on classification, prevalence ranged from 47% (57/122, definite or predisposition) to 64% (78/122, including uncertain/possible pathogenic variants). Neither clinical dimensions nor severity clusters were associated with the presence of genetic abnormalities. Conclusion:Despite a referral bias toward severe cases, the high rate of genetic findings in this cohort underscores the need for more systematic genetic testing in complex NDD with multidimensional impairment.</p></div>","PeriodicalId":652,"journal":{"name":"Journal of Molecular Neuroscience","volume":"75 4","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Molecular Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12031-025-02424-6","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: Many children with neurodevelopmental disorders (NDD) show complex, multidimensional impairments meeting criteria for multiple NDD, yet remain “diagnostically homeless” as DSM-5 lacks a Multidimensional Impairment (MDI) category. We investigated the prevalence of genetic abnormalities in such complex NDD cases. Methods:Between 2017 and 2019, we diagnosed MDI in 666 patients. Among them, 122 (18%) underwent genetic assessment (DNA microarrays, karyotype, gene panels, FISH, FMR1 testing, exome/genome sequencing). We used univariate analyses and clustering to explore associations between clinical dimensions and genetic findings. Results: Genetic abnormalities were identified in 78 patients. Of these:

  1. (1)

    41 had known abnormalities usually linked to complex NDD (e.g., del22q11.2);

  2. (2)

    16 had mutations associated with severe ASD/ID (e.g., GRIA3 on Xq25);

  3. (3)

    11 showed novel abnormalities not previously linked to NDD (e.g., duplication Xq21.1 including POU3F4);

  4. (4)

    10 had variants of uncertain significance.

Depending on classification, prevalence ranged from 47% (57/122, definite or predisposition) to 64% (78/122, including uncertain/possible pathogenic variants). Neither clinical dimensions nor severity clusters were associated with the presence of genetic abnormalities. Conclusion:Despite a referral bias toward severe cases, the high rate of genetic findings in this cohort underscores the need for more systematic genetic testing in complex NDD with multidimensional impairment.

Abstract Image

神经发育障碍伴多维损害的遗传异常
目的:许多患有神经发育障碍(NDD)的儿童表现出复杂的、符合多重NDD标准的多维损害,但由于DSM-5缺乏多维损害(MDI)类别,他们仍然“被诊断为无家可归”。我们调查了遗传异常在这些复杂的NDD病例中的患病率。方法:在2017年至2019年期间,我们在666例患者中诊断出MDI。其中122例(18%)进行了遗传评估(DNA微阵列、核型、基因面板、FISH、FMR1检测、外显子组/基因组测序)。我们使用单变量分析和聚类来探索临床维度和遗传发现之间的关联。结果:78例患者发现遗传异常。其中:(1)41例已知异常通常与复杂的NDD有关(例如,del22q11.2);(2) 16个基因存在与严重ASD/ID相关的突变(如Xq25上的GRIA3);(3) 11例显示以前未与NDD联系的新异常(例如,重复Xq21.1,包括POU3F4);(4)有10个具有不确定意义的变体。根据分类,患病率从47%(57/122,明确或易感性)到64%(78/122,包括不确定/可能的致病变异)不等。临床维度和严重程度群集都与遗传异常的存在无关。结论:尽管转诊偏向于重症病例,但该队列中较高的遗传发现率强调了在复杂的NDD中进行更系统的基因检测的必要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Molecular Neuroscience
Journal of Molecular Neuroscience 医学-神经科学
CiteScore
6.60
自引率
3.20%
发文量
142
审稿时长
1 months
期刊介绍: The Journal of Molecular Neuroscience is committed to the rapid publication of original findings that increase our understanding of the molecular structure, function, and development of the nervous system. The criteria for acceptance of manuscripts will be scientific excellence, originality, and relevance to the field of molecular neuroscience. Manuscripts with clinical relevance are especially encouraged since the journal seeks to provide a means for accelerating the progression of basic research findings toward clinical utilization. All experiments described in the Journal of Molecular Neuroscience that involve the use of animal or human subjects must have been approved by the appropriate institutional review committee and conform to accepted ethical standards.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信